JP6942053B2 - 原発性硬化性胆管炎を治療する方法 - Google Patents

原発性硬化性胆管炎を治療する方法 Download PDF

Info

Publication number
JP6942053B2
JP6942053B2 JP2017546181A JP2017546181A JP6942053B2 JP 6942053 B2 JP6942053 B2 JP 6942053B2 JP 2017546181 A JP2017546181 A JP 2017546181A JP 2017546181 A JP2017546181 A JP 2017546181A JP 6942053 B2 JP6942053 B2 JP 6942053B2
Authority
JP
Japan
Prior art keywords
antibody
dose
psc
seq
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017546181A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018508526A (ja
JP2018508526A5 (https=
Inventor
アブヤンカー，ブリハッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2018508526A publication Critical patent/JP2018508526A/ja
Publication of JP2018508526A5 publication Critical patent/JP2018508526A5/ja
Application granted granted Critical
Publication of JP6942053B2 publication Critical patent/JP6942053B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2017546181A 2015-03-06 2016-03-04 原発性硬化性胆管炎を治療する方法 Active JP6942053B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562129698P 2015-03-06 2015-03-06
US62/129,698 2015-03-06
PCT/US2016/020819 WO2016144720A1 (en) 2015-03-06 2016-03-04 Method of treating primary sclerosing cholangitis

Publications (3)

Publication Number Publication Date
JP2018508526A JP2018508526A (ja) 2018-03-29
JP2018508526A5 JP2018508526A5 (https=) 2019-04-11
JP6942053B2 true JP6942053B2 (ja) 2021-09-29

Family

ID=55699788

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017546181A Active JP6942053B2 (ja) 2015-03-06 2016-03-04 原発性硬化性胆管炎を治療する方法

Country Status (11)

Country Link
US (2) US20180051086A1 (https=)
EP (2) EP4257200A3 (https=)
JP (1) JP6942053B2 (https=)
KR (1) KR20170120622A (https=)
AU (1) AU2016229193A1 (https=)
BR (1) BR112017019071A2 (https=)
CA (1) CA2978725A1 (https=)
EA (1) EA201791970A1 (https=)
MA (1) MA41636A (https=)
MX (1) MX2017011272A (https=)
WO (1) WO2016144720A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
IL261750B2 (en) * 2016-03-14 2024-07-01 Millennium Pharm Inc Method of preventing graft versus host disease
BR112018068625A2 (pt) * 2016-03-14 2019-07-30 Millennium Pharm Inc métodos de tratamento ou prevenção de doença de enxerto contra hospedeiro
CN109414502A (zh) 2016-06-12 2019-03-01 千禧制药公司 治疗炎症性肠病的方法
EP3956358A4 (en) * 2019-04-17 2023-01-25 Millennium Pharmaceuticals, Inc. COMBINATION THERAPY WITH ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR
US20220267449A1 (en) * 2019-06-10 2022-08-25 Takeda Pharmaceutical Company Limited METHODS OF PRODUCING AN ANTI-a4B7 ANTIBODY
WO2022075756A1 (ko) 2020-10-08 2022-04-14 주식회사 큐롬바이오사이언스 베타-라파촌을 유효성분으로 포함하는 담즙 정체성 간질환 예방 또는 치료용 약학 조성물
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
EP0808367B1 (en) 1995-02-10 2007-07-11 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US7090845B2 (en) 1998-05-13 2006-08-15 Genentech, Inc. Diagnosis and treatment of hepatic disorders
DE69940503D1 (de) * 1998-05-13 2009-04-16 Genentech Inc Diagnose und behandlung von hepatischen krankheiten
EP2399903A1 (en) 2002-05-24 2011-12-28 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
US6939885B2 (en) 2002-11-18 2005-09-06 Chemocentryx Aryl sulfonamides
RS52213B (sr) 2004-09-03 2012-10-31 Genentech, Inc. Humanizovani anti-beta7 antagonisti i njihove primene
JP2009515552A (ja) * 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
CN103382222B (zh) 2009-03-20 2016-12-28 安姆根有限公司 α-4-β-7异二聚体特异性拮抗剂抗体
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
DK3311834T3 (da) 2011-05-02 2026-04-20 Millennium Pharmaceuticals Inc Formulering til anti-alfa4beta7-antistof
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive

Also Published As

Publication number Publication date
EP3265492A1 (en) 2018-01-10
JP2018508526A (ja) 2018-03-29
MX2017011272A (es) 2018-01-12
US20180051086A1 (en) 2018-02-22
US12391760B2 (en) 2025-08-19
KR20170120622A (ko) 2017-10-31
EP4257200A3 (en) 2024-01-03
US20210388092A1 (en) 2021-12-16
EA201791970A1 (ru) 2018-07-31
EP4257200A2 (en) 2023-10-11
WO2016144720A1 (en) 2016-09-15
AU2016229193A1 (en) 2017-09-21
BR112017019071A2 (pt) 2018-04-17
MA41636A (fr) 2018-01-09
CA2978725A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
JP6942053B2 (ja) 原発性硬化性胆管炎を治療する方法
US20260055198A1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
US20240376210A1 (en) Vedolizumab for the treatment of fistulizing crohn's disease
JP6306070B2 (ja) 進行型多発性硬化症の治療方法
AU2018311688B2 (en) Methods and compositions for treatment of amyloid deposition diseases
MX2013011130A (es) Metodos de administracion de antagonistas de integrina beta7.
US20200179486A1 (en) Method of treating pediatric disorders
JP2025170299A (ja) 多発性硬化症を治療するための方法
JP7202893B2 (ja) 炎症性腸疾患を治療する方法
US20240209091A1 (en) Methods for treating cancer using anti-ctla4 antibodies
AU2019291305B2 (en) Methods for improving response to anti-LIF antibody treatment in individuals with cancer
WO2025074337A1 (en) Use of anti-sirp-alpha antibodies to treat a liver disease or disorder
TW202448506A (zh) 以抗ｔｉｇｉｔ抗體治療腫瘤之方法
IL271284B (en) Methods of treating or preventing asthma by administering an antagonist to -il-r4

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20190301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190301

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20190611

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200323

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210420

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210817

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210907

R150 Certificate of patent or registration of utility model

Ref document number: 6942053

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250